|
US633410A
(en)
|
1898-09-22 |
1899-09-19 |
George A Ames |
Ice-cutter.
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US4957735A
(en)
|
1984-06-12 |
1990-09-18 |
The University Of Tennessee Research Corporation |
Target-sensitive immunoliposomes- preparation and characterization
|
|
US5019369A
(en)
|
1984-10-22 |
1991-05-28 |
Vestar, Inc. |
Method of targeting tumors in humans
|
|
US4902505A
(en)
|
1986-07-30 |
1990-02-20 |
Alkermes |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
|
JP3040121B2
(ja)
|
1988-01-12 |
2000-05-08 |
ジェネンテク，インコーポレイテッド |
増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
|
|
US5055303A
(en)
|
1989-01-31 |
1991-10-08 |
Kv Pharmaceutical Company |
Solid controlled release bioadherent emulsions
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5271961A
(en)
|
1989-11-06 |
1993-12-21 |
Alkermes Controlled Therapeutics, Inc. |
Method for producing protein microspheres
|
|
US5188837A
(en)
|
1989-11-13 |
1993-02-23 |
Nova Pharmaceutical Corporation |
Lipsopheres for controlled delivery of substances
|
|
US5268164A
(en)
|
1990-04-23 |
1993-12-07 |
Alkermes, Inc. |
Increasing blood-brain barrier permeability with permeabilizer peptides
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US5254342A
(en)
|
1991-09-30 |
1993-10-19 |
University Of Southern California |
Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
|
|
JPH07507768A
(ja)
|
1992-03-12 |
1995-08-31 |
アルカーメス コントロールド セラピューティクス，インコーポレイテッド |
Ａｃｔｈ含有マイクロスフェアの制御放出
|
|
US5534496A
(en)
|
1992-07-07 |
1996-07-09 |
University Of Southern California |
Methods and compositions to enhance epithelial drug transport
|
|
US5514670A
(en)
|
1993-08-13 |
1996-05-07 |
Pharmos Corporation |
Submicron emulsions for delivery of peptides
|
|
CN1260249C
(zh)
|
1998-05-06 |
2006-06-21 |
基因技术股份有限公司 |
用离子交换层析纯化蛋白质
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
JP2006500364A
(ja)
|
2002-08-16 |
2006-01-05 |
イムノージェン インコーポレーテッド |
高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
AU2005249490B2
(en)
|
2004-06-01 |
2010-07-29 |
Genentech, Inc. |
Antibody drug conjugates and methods
|
|
ZA200701234B
(en)
|
2004-07-22 |
2008-12-31 |
Genentech Inc |
HER2 antibody composition
|
|
CA2580141C
(en)
|
2004-09-23 |
2013-12-10 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
|
DK2644194T3
(en)
|
2008-03-18 |
2017-07-03 |
Genentech Inc |
Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
|
|
EP2247304B1
(en)
|
2008-04-02 |
2016-05-25 |
MacroGenics, Inc. |
Her2/neu-specific antibodies and methods of using same
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
KR20200003245A
(ko)
|
2011-10-14 |
2020-01-08 |
어레이 바이오파마 인크. |
선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물
|
|
SI2765990T1
(sl)
|
2011-10-14 |
2017-11-30 |
Array Biopharma, Inc. |
Trdna disperzija
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
KR102306490B1
(ko)
|
2013-03-15 |
2021-09-28 |
리제너론 파아마슈티컬스, 인크. |
생물학적 활성 분자, 그의 접합체 및 치료 용도
|
|
WO2014200891A1
(en)
|
2013-06-11 |
2014-12-18 |
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH & HUMAN SERVICES |
Her2-specific monoclonal antibodies and conjugates thereof
|
|
CA2921412C
(en)
|
2013-08-26 |
2024-05-28 |
Regeneron Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
|
|
EP3480215B8
(en)
|
2013-11-19 |
2021-07-28 |
RemeGen Co., Ltd. |
Anti-her2 antibody and conjugate thereof
|
|
CR20160271A
(es)
|
2013-12-16 |
2016-12-02 |
Genentech Inc |
Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
|
|
HUE029672T2
(en)
|
2014-01-10 |
2017-03-28 |
Synthon Biopharmaceuticals Bv |
Duokarmicin-ADCs for use in the treatment of endometrial cancer
|
|
SI3466976T1
(sl)
|
2014-01-31 |
2021-12-31 |
Daiichi Sankyo Company, Limited |
Anti-her2 konjugat protitelesa-zdravila
|
|
MX2016012830A
(es)
|
2014-04-11 |
2017-01-05 |
Medimmune Llc |
Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
|
|
CN107001479B
(zh)
|
2014-09-12 |
2021-09-28 |
基因泰克公司 |
抗her2抗体和免疫缀合物
|
|
MX2017012380A
(es)
|
2015-03-27 |
2018-04-11 |
Regeneron Pharma |
Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
|
|
CN108779127B
(zh)
|
2016-01-25 |
2022-07-05 |
里珍纳龙药品有限公司 |
美登素类化合物衍生物、其偶联物和使用方法
|
|
AU2017341000A1
(en)
|
2016-10-07 |
2019-04-11 |
Daiichi Sankyo Company, Limited |
Therapy for drug-resistant cancer by administration of anti-HER2 antibody/drug conjugate
|
|
AU2019262953A1
(en)
|
2018-04-30 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof
|